Chapter 20.2 -Acute lymphoblastic leukaemia in children and adolescents

ESH eLearning, Christina Peters, 165697

Chapter 20.1 - Acute myeloid leukaemia

ESH eLearning, Giorgio Dini and Stefano Giardino, 165696

Chapter 19.12 - Aplastic anaemia and paroxysmal nocturnal haemoglobinuria

ESH eLearning, Judith Marsh, 165695

Chapter 19.11 - Autoimmune diseases

ESH eLearning, John A. Snowden, Riccardo Sacc Dominique Farge, 165694

Chapter 19.10 - Solid tumours in adults

ESH eLearning, Marco Bregni, 165693

Chapter 19.9 - HSCT for Hodgkin’s lymphoma in adults

ESH eLearning, Anna Sureda and Harry C. Schouten, 165692

Chapter 19.8 - HSCT for non-Hodgkin’s lymphoma

ESH eLearning, Harry C. Schouten and Anna Sureda, 165691

Chapter 19.7 - Role of HSCT in primary amyloidosis

ESH eLearning, M. Teresa Cibeira and Jordi Esteve, 165690

Chapter 19.6 - Multiple myeloma

ESH eLearning, Jesús San-Miguel, José A. Pére M. Victoria Mateos, 165689

Chapter 19.5 - Chronic lymphocytic leukaemia

ESH eLearning, Peter Dreger and Johannes Schetelig, 165688

Chapter 19.4 - Chronic myeloid leukaemia and the myeloproliferative disorders

ESH eLearning, Jiri Pavlu and Jane Apperley, 165687

Chapter 19.3 - HSCT for myelodysplastic syndromes

ESH eLearning, Nicolaus Kröger, 165686

Chapter 19.2 - Acute lymphoblastic leukaemia

ESH eLearning, M Mohty, 165685

Chapter 19.1 - Acute myeloid leukaemia

ESH eLearning, M Mohty, 165684

Chapter 18 - Indications for and current practice of allogeneic and autologous HSCT

ESH eLearning, Alois Gratwohl, Helen Baldomer Anna Sureda, 165683

Chapter 17 – Immunotherapy post-transplant

ESH eLearning, Inge Jedema and J.H. Frederik Falkenburg, 165682

Chapter 16.2 - Chimerism

ESH eLearning, Thomas Lion, 165681

Chapter 16.1 - Molecular monitoring of minimal residual disease

ESH eLearning, Jean-Michel Cayuela, 165680

Chapter 15 - Late effects in patients treated with HSCT

ESH eLearning, Andre Tichelli, 165679

Chapter 14 - Immune reconstitution after allogeneic HSCT

ESH eLearning, Antoine Toubert, 165678

Chapter 13 - Graft-versus-host disease

ESH eLearning, Jane Apperley and Tamas Masszi, 165677

Chapter 12 - Infections after HSCT

ESH eLearning, Montserrat Rovira, Josep Mensa Enric Carreras, 165676

Chapter 11 - Early complications after HSCT

ESH eLearning, Enric Carreras, 165675

Chapter 10 - Supportive care

ESH eLearning, Tamas Masszi and Arno Mank, 165674

Chapter 9 - Transfusion support in patients undergoing HSCT

ESH eLearning, Rachel Pawson and Derwood Pamphilon, 165673

Chapter 8 - Principles of conditioning

ESH eLearning, Alois Gratwohl and Enric Carreras, 165672

Chapter 7 - Bone marrow donor registries and cord blood banks

ESH eLearning, Carlheinz Mueller and Sergio Querol, 165671

Chapter 6 - Choice of the donor according to HLA typing and stem cell source

ESH eLearning, eliane Gluckman, 165670

Chapter 5 - Immunogenetics of allogeneic HSCT

ESH eLearning, Bronwen E. Shaw Alejandro Madrigal, 165669

Chapter 4 - Biological properties of haematopoietic stem cells

ESH eLearning, Aleksandra Wodnar-Filipowicz, 165668

Chapter 3 - JACIE & quality management in HSCT

ESH eLearning, Christian Chabannon Eoin McGrath, 165667

Chapter 2 - Present and future

ESH eLearning, Alejandro Madrigal Anna Sureda, 165666

Chapter 1 - A brief history of HSCT

ESH eLearning, eliane Gluckman, 165665

Cord blood transplant and very rare anaemias

ESH eLearning, Annalisa Ruggeri, 17976

Quality controls for the diagnosis of rare red cell disorders

ESH eLearning, Andrea Mosca, 17974

Paroxysmal Nocturnal Haemoglobinuria

ESH eLearning, Regis Peffault de Latour, 17973

Microangiopathic haemolytic anaemias - TTP, HUS ( haemolytic uraemic syndrome)

ESH eLearning, Paul Coppo, 17972

Autoimmune haemolytic anaemias by warm antibodies

ESH eLearning, Norbert Ahrens, 17970

Cold-antibody mediated autoimmune hemolytic anemia

ESH eLearning, Sigbjorn Berentsen, 17971

Clinical case 3

ESH eLearning, Joan-LLuis Vives-Corrons, 17969

Clinical case 2

ESH eLearning, A. A. M. Ermens, 19900

Clinical Case 1

ESH eLearning, R van Wijk, 19899

Normal and defective red blood cell metabolism abnormalities of glycolysis and the generation of reduced glutathione

ESH eLearning, R van Wijk, 17968

Closing talk of Day 1

ESH eLearning, Joan-LLuis Vives-Corrons, 17967

Erythropoietic porphyrias

ESH eLearning, Jean Charles Deybach, 17966

Clinical cases of membrane disorders

ESH eLearning, Alberto Zanella & Leticia Ribeiro, 19868

Hereditary elliptocytosis, pyropoikilocytosis and South-East Asian Ovalocytosis

ESH eLearning, Leticia Ribeiro, 17963

Hereditary spherocytosis

ESH eLearning, Alberto Zanella, 17962

Iron overload and chelation therapy

ESH eLearning, Maria Domenica Cappellini, 19866

Clinical cases

ESH eLearning, Maria Domenica Cappellini, 17961

Hereditary sideroblastic anaemias

ESH eLearning, Alison May, 17960

Rare inherited anaemias due to defects in the erythroblastiron acquisition pathway

ESH eLearning, Carole Beaumont, 17959

What are very rare anaemias ?

ESH eLearning, GULBIS BEATRICE, 17954

Welcome to Participants

ESH eLearning, Patricia Aguilar-Martinez, 19865

Recurrent fetal loss and thrombophilia

ESH eLearning, Saskia Middeldorp, 17339

Novel antithrombotic drugs

ESH eLearning, Sylvia Haas, 17338

Disseminated intravascular coagulation

ESH eLearning, Marcel Levi, 17337

Antiphospholipid syndrome

ESH eLearning, Ph G. de Groot, 17335

Cancer and thrombosis

ESH eLearning, Anna Falanga, 17334

Arterial thrombosis, pathogenesis, epidemiology

ESH eLearning, Gordon Lowe, 17330

Venous Thrombosis: etiology, pathogenesis and prognosis

ESH eLearning, Frits Rosendaal, 17328

Genetic risk factors of arterial and venous thrombosis

ESH eLearning, Pieter Reitsma, 17327

Control Mechanisms of coagulation

ESH eLearning, Bjorn Dahlback, 17326

Inherited platelet bleeding disorders, diagnosis and treatment

ESH eLearning, Alan Nurden, 17325

Management of coagulation disorders, complications and prevention

ESH eLearning, Pier Mannucci, 17323

Rare Bleeding Disorders

ESH eLearning, Flora Peyvandi, 17322

Molecular genetics of coagulation

ESH eLearning, Pieter Reitsma, 17320

Biochemistry of the coagulation systems

ESH eLearning, David Lane, 17319

Stopping TKI can now be recommended in selected partients: no

ESH eLearning, Giuseppe Saglio, 12583

Stopping TKI can now be recommended in selected patients: yes

ESH eLearning, François-Xavier Mahon, 12581

Debate

ESH eLearning, Session Speakers, 12606

Maintenance of a stable CCyR is an adequate therapeutic target: no

ESH eLearning, Philippe Rousselot, 12585

Maintenance of a stable CCyR is an adequate therapeutic target: yes

ESH eLearning, Michele Baccarani, 12584

All CML patients should start treatment with 2G-TKI: no

ESH eLearning, charles schiffer, 12586

Residual normal stem cells can be detected in newly diagnosed CML patients by a new flow cytometric approach and predict for optimal response to imatinib

ESH eLearning, Jeroen Janssen, 12601

The Prognostic significance of Molecular and Cytogenetic response landmarks after 3 month of Imatinib in the upfront treatment of CML

ESH eLearning, Benjamin Hanfstein, 12598

Switching to nilotinib vs imatinib dose escalation for patients with suboptimal treatment response to imatinib: 24 month update of the TIDEL-II trial

ESH eLearning, David T Yeung, 12596

High BCR-ABLIS expression levels at diagnosis and after 3 and 6 months of treatment are associated with an unfavourable response to imatinib

ESH eLearning, Paolo Vigneri, 12597

Correlation of hOCT1 genetic polymorphisms with the clinical outcome Athina Giannoudis (Liverpool) of CML patients treated with imatinib

ESH eLearning, Athina Giannoudis, 12595

BCR-ABL compound mutations in CML

ESH eLearning, Jamshid Khorashad, 12594

Debate

ESH eLearning, Session Speakers, 12604

JAK-2 is clearly an important therapeutic target in CML: no

ESH eLearning, Wolfgang Warsch, 12592

JAK-2 is clearly an important therapeutic target in CML: yes

ESH eLearning, MIN CHEN, 12590

There is a definite need to target stem cells: no

ESH eLearning, Giovanni Martinelli, 12588

CML . Reminiscences and dreams

ESH eLearning, John Goldman, 12532

Finding the soft spot: targeting CML stem cells

ESH eLearning, Mike Deininger, 12534

A novel AHI-1-BCR-ABL-JAK2 interaction complex mediates cellular resistance to tyrosine kinase inhibitors in CML stem/progenitor cells

ESH eLearning, MIN CHEN, 12535

BCL6 is required for the initiation and maintenance of CML

ESH eLearning, Christian Hurtz, 12536

Targeting of a novel MNK-eIF4E-b-catenin axis in blast crisis CML inhibits leukimia stem cell funcation

ESH eLearning, Sharon Lim, 12542

Evaluation of the efficacy and mechanism of action of the JAK2 inhibitor INCB18424 in primary CML stem/progenitor cells

ESH eLearning, Paolo Gallipoli, 12544

Keynote lecture: 10 years of imatinib resistance- heaps of mutations and a dozen new TKI : what we have learned . a biochemist.s view

ESH eLearning, Oliver Hantschet, 12558

Rac2 - mitochondrial respiratory chain complex III signaling generates reactive oxygen species causing genomic instability in CML-CP leukemia stem and progenitor cells

ESH eLearning, Piotr Kopinski, 12561

Targeting STAT5 in CML: Mechanism-of-action of JAK2 tyrosine kinase inhibitors in CML unmask a direct BCR-ABL/STAT5 axis

ESH eLearning, Wolfgang Warsch, 12562

Regulation of mature versus immature conformation of BCR-ABL

ESH eLearning, Yoshiro Maru, 12563

Man versus machine: a semi-automated platform for BCR-ABL QPCR

ESH eLearning, Jerry Radich, 12566

Distinct graft-vs-leukimic stem cell of early or delayed donor leukocyte infusions in amouse CML model

ESH eLearning, Yi-Fen Lu, 12570

The BELA trial: 18-month update on safety and clinical activity in patients with chronic phase CML treated with bosutirub (SKI-606) or imatinib

ESH eLearning, C Gambacorti, 12571

Updated phase 1 data on ponatinib, a pan-BCR-ABL inhibitor, in CML and other hematologic malignancies

ESH eLearning, Jorge Cortes, 12572

Multiple non-resistant low-level BCR-ABL1 mutations in CML patients after imatinib resitance predict poor response and high risk of new resistant mutations during the second-lin kinase inhibitor therapy

ESH eLearning, Susan Branford, 12574

A Phase 1 study of DCC-2036, an oral novel inhibitor of Abl kinase, in adult patients with Philadelphia Chromosome Positive (Ph+) CML including patients with T315I mutation

ESH eLearning, Jorge Cortes, 12578